Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: Pathology of the explant livers and clinical outcome

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 2, 2005, Pages 209-214

  Lambert, Bieke ^a   Praet, Marleen ^a   Vanlangenhove, Peter ^a   Troisi, Roberto ^a   De Hemptinne, Bernard ^a   Gemmel, Filip ^a   Van Vlierberghe, Hans ^a   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hepatocellular carcinoma; Iodine 131 lipiodol; Liver transplantation; Radionuclide therapy; Rhenium 188 HDD lipiodol

Indexed keywords

4 HEXADECYL 2,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANEDITHIOL RE 188; ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY CATHETERIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; EXPLANT; FEMALE; FOLLOW UP; HEPATIC ARTERY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER NECROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; PATHOLOGY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODIZED OIL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NECROSIS; RADIOISOTOPES; TIME FACTORS; TREATMENT OUTCOME;

EID: 18844400318     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.209     Document Type: Conference Paper

References (21)

1. Parkin MD, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253.
3. Little SA, Fong Y. Hepatocellular carinoma: Current surgical management. Semin Oncol 2001;28:474.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;334:697.
5. Figueras J, Jaurrieta E, Valls C, et al. Hepatology 1997;25:1485.
6. Haug CE, Jenkins RL, Rohrer RJ, et al. Liver transplantation for primary hepatic cancer. Transplantation 1992;53:376.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907.
8. Wall WJ, Marotta PJ. Surgery and transplantation for hepatocellular cancer. Liver Transpl 2000;6:S16.
9. Llovet JM, Mas X, Aponte JJ, et al. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123.
10. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-I-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156.
11. 131I-lipiodol treatment for hepatocellular carcinoma: A pilot study. Cancer Biother Radiopharm 2001;16:333.
12. Raoul JL, Messner M, Boucher E, et al. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 1131-labeled lipiodol. Br J Surgery 2003;90:1379.
13. 188Re-labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237.
14. Fisher RA, Maluf D, Cotterell AH, et al. Nonresective ablation therapy for hepatocellular carcinoma: Effectiveness measured by intention-to-treat and drop-out from liver transplant waiting list. Clin Transpl 2004;18:502.
15. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001;33:1073.
16. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular carcinoma: The impact of the MELD allocation policy. Gastroenterology 2004;127:8261.
17. Nonami T, Isshiki K, Katoh H, et al. The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg 1991;213:222.
18. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S268.
19. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561.
20. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 1999;353:797.
21. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: A phase I clinical trial. J Nucl Med 2005;46:60.